Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Imatinib

Imatinib Reactions 1704, p192 - 2 Jun 2018 Philadelphia chromosome-negative acute promyelocytic leukaemia: case report A 59-year-old man developed Philadelphia (Ph) chromosome-negative acute promyelocytic leukaemia following treatment with imatinib [route not stated]. The man, who was diagnosed with chronic myeloid leukaemia (CML) at the age of 51 years, had been receiving imatinib 300–400 mg/day [exact dosage not stated]. He had been maintaining complete molecular response since 30 months post the diagnosis of CML. Subsequently, a bone marrow aspirate revealed increased abnormal promyelocytes with azurophilic granules and Auer rods. The results of subsequent fluorescence in situ hybridisation (FISH) test and PCR test were consistent with the diagnosis of Ph-negative APL. The FISH test and PCR test detected PML-RARA; the translocation breakpoint was located in PML intron 6. It was suspected that the Ph-negative APL was due to the administration of imatinib [duration of treatment to reaction onset not stated]. The man was treated with induction chemotherapy with all- trans retinoic acid, followed by one cycle of consolidation therapy, respectively. Following the chemotherapy, the PML- RARA became undetectable by FISH and PCR. The imatinib therapy was discontinued. Author comment: "Here, we describe a case of Ph- negative acute promyelocytic leukemia (APL) observed http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Imatinib

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018

Imatinib

Abstract

Reactions 1704, p192 - 2 Jun 2018 Philadelphia chromosome-negative acute promyelocytic leukaemia: case report A 59-year-old man developed Philadelphia (Ph) chromosome-negative acute promyelocytic leukaemia following treatment with imatinib [route not stated]. The man, who was diagnosed with chronic myeloid leukaemia (CML) at the age of 51 years, had been receiving imatinib 300–400 mg/day [exact dosage not stated]. He had been maintaining complete molecular response since 30 months post...
Loading next page...
 
/lp/springer_journal/imatinib-jMocsJs1sx
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46835-5
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p192 - 2 Jun 2018 Philadelphia chromosome-negative acute promyelocytic leukaemia: case report A 59-year-old man developed Philadelphia (Ph) chromosome-negative acute promyelocytic leukaemia following treatment with imatinib [route not stated]. The man, who was diagnosed with chronic myeloid leukaemia (CML) at the age of 51 years, had been receiving imatinib 300–400 mg/day [exact dosage not stated]. He had been maintaining complete molecular response since 30 months post the diagnosis of CML. Subsequently, a bone marrow aspirate revealed increased abnormal promyelocytes with azurophilic granules and Auer rods. The results of subsequent fluorescence in situ hybridisation (FISH) test and PCR test were consistent with the diagnosis of Ph-negative APL. The FISH test and PCR test detected PML-RARA; the translocation breakpoint was located in PML intron 6. It was suspected that the Ph-negative APL was due to the administration of imatinib [duration of treatment to reaction onset not stated]. The man was treated with induction chemotherapy with all- trans retinoic acid, followed by one cycle of consolidation therapy, respectively. Following the chemotherapy, the PML- RARA became undetectable by FISH and PCR. The imatinib therapy was discontinued. Author comment: "Here, we describe a case of Ph- negative acute promyelocytic leukemia (APL) observed

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References